India's customs authority has moved to strengthen the health ministry's position in a regulatory standoff with billionaire Gautam Adani's airport operations, contending that duty-free retail privileges confer no exemption from the country's product approval requirements. The filing submitted to Mumbai's High Court on June 22 marks a significant escalation in the dispute, as a second major government agency now disputes Adani's assertion that goods sold in international departure zones fall outside domestic regulatory jurisdiction. The disagreement centres on whether nicotine pouches—highly addictive products that lack approval in India—may legally be sold to passengers departing from Mumbai's international airport.
The controversy erupted following a March inspection by health ministry officials at Adani's Mumbai airport, where inspectors documented the sale of nicotine pouches at duty-free outlets and determined the practice violated Indian law. Rather than comply with the directive, Adani Group initiated a legal challenge at Mumbai's High Court, positioning the dispute as a matter of jurisdiction and commercial rights. The company's legal strategy hinges on the argument that international departure areas operate within a separate regulatory space, subject only to customs tariff rules rather than India's broader consumer protection and pharmaceutical approval frameworks. This interpretation, if accepted, would create a significant loophole for products banned or unapproved domestically.
The customs department's position, articulated in court filings, directly undermines this logic. Officials contend that the tax and tariff privileges afforded to duty-free commerce exist purely for revenue purposes and carry no implication of regulatory immunity. The critical distinction, from the government's perspective, is between who collects taxes on goods and who enforces product safety and approval standards. Customs jurisdiction over taxation does not dissolve health ministry oversight of potentially harmful substances. This framing attempts to close what health officials regard as a dangerous interpretive gap that could transform international departure areas into unregulated marketplaces.
Adani's legal arguments have evolved across multiple court filings. In July, the company presented a more detailed defence, suggesting that customs authorities had overstepped by issuing directives to halt sales without first issuing formal warning notices—a procedural requirement under Indian administrative law. The group further contended that nicotine pouches sold in duty-free shops are technically intended for consumption outside India's borders, placed in sealed packaging with explicit instructions restricting use until international airspace. Under this logic, passengers purchasing such products do so with the understanding they will consume them abroad, rendering India's domestic regulations inapplicable. The reasoning echoes arguments frequently made by duty-free retailers globally when defending sales of restricted products.
Customs authorities have characterised this interpretation as fundamentally flawed. Officials note that once passengers take possession of duty-free goods, they retain complete freedom to use them immediately, during their journey, or upon arrival at any destination. The sealed packaging and theoretical restrictions on use cannot be enforced post-sale and do not alter the reality that Indian citizens purchasing these items will almost certainly consume them within India or transport them across borders. From a practical standpoint, the customs position reflects the acknowledged reality that duty-free shopping serves primarily as a tax arbitrage mechanism for affluent travellers, not a mechanism for exporting goods.
Nicotine pouches represent one of the world's fastest-expanding categories within the broader nicotine consumption market, capitalising on regulatory gaps and consumer demand for smokeless alternatives. Philip Morris, the market leader through its Zyn brand, has reported remarkable growth in the United States, where sales doubled in 2024 compared to the previous year. This trajectory reflects successful marketing to younger demographics and those seeking alternatives to traditional cigarettes or e-cigarettes. India's substantial middle-class population and rising purchasing power have made the market an attractive target for manufacturers, particularly through the high-traffic, high-income channels provided by international airports.
Adani Group's commercial exposure to this emerging category is substantial and expanding. Company records analysed by Reuters show imports of Zyn and White Fox nicotine pouches from Swedish Smokeless Solutions exceeding $35,000 since August, indicating the group views this product category as a growth opportunity within its duty-free retail strategy. The expansion is occurring against the backdrop of Adani's broader airport infrastructure ambitions, which include an $11 billion investment programme that explicitly prioritises duty-free retail revenue streams. For a company betting heavily on airport retail expansion, the regulatory challenge threatens not merely one product line but the fundamental commercial model underlying the airport retail business case.
The timing and coordination of the regulatory action carry particular significance for Southeast Asian observers. As regional airport operators and retailers across Malaysia, Singapore, Thailand, and Indonesia expand duty-free operations and increasingly source similar products, the Adani dispute may establish important precedents regarding regulatory authority over international retail zones. Several countries in the region have similarly unapproved nicotine pouches, raising questions about whether their own airport operators might face comparable challenges. The case effectively tests whether customs and health authorities can align to prevent duty-free zones from becoming de facto regulatory black holes.
India's position, should it prevail, would establish that product approval requirements apply universally within national jurisdiction, irrespective of tax treatment. This principle carries implications extending far beyond nicotine pouches. Duty-free retailers have traditionally operated in jurisdictional grey zones, often importing products that would face import restrictions if sold through conventional retail channels. If Indian courts accept the argument that regulatory oversight applies uniformly, while customs simply exercises discretion regarding taxation, the precedent could reshape duty-free operations globally. Retailers would face pressure to conform products to the regulatory standards of the country where they operate, even for goods destined for consumption abroad.
The next hearing, scheduled for July 28, will determine whether the court intends to accept the health ministry and customs position or sides with Adani's interpretation of jurisdictional boundaries. The outcome will likely influence similar disputes across South Asia and potentially throughout the region. For Adani Group specifically, an unfavourable decision would necessitate removing nicotine pouches from its airport retail portfolio, representing a symbolic and financial setback within its broader airport commerce strategy. For the Indian health authorities, the case represents an opportunity to establish that regulatory reach extends into commercial spaces that exploit tax advantages but remain embedded within the national territory.
